

DISCUSSIONS WITH LEADERS

- 1671 Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo**
Kalevi Kairemo and Johannes Czernin

HOT TOPICS

- 1674 FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders**
Christian Schmidkonz, Armin Atzinger, Andreas Ramming, and Torsten Kuwert

FOCUS ON MOLECULAR IMAGING

- 1676 The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection**
Alberto Signore, Alvaro A. Ordonez, Chanda Arjun, Gurpreet Kaur Aulakh, Nicolas Beziere, Ekaterina Dadachova, Thomas Ebenhan, Ulises Granados, Aruna Korde, Amirreza Jalilian, et al.

ONCOLOGY

Clinical

- 1683 Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using ¹⁸F-FET PET**
Johannes Lohmeier, Helena Radbruch, Winfried Brenner, Bernd Hamm, Anna Tietze, and Marcus R. Makowski
- 1690 Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)**
Maeve A. Hennessy, Jeffrey P. Leal, Chiung-Yu Huang, Lilja B. Solnes, Rita Denbow, Vandana G. Abramson, Lisa A. Carey, Minetta C. Liu, Mothaffar Rimawi, Jennifer Specht, et al.
- 1697 ■ INVITED PERSPECTIVE. ¹⁸F-FDG PET “Metabolic Response” to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?**
Geraldine Gebhart
- 1699 High Tumor Uptake on ¹⁸F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network**
Ophélie De Rycke, Marine Perrier, Éric Ouvrard, Clément Menntrey, Choaib Lachachi, Aurélie Bando-Delaunay, David Morland, Bernard Goichot, David Taieb, Thomas Walter, et al.
- 1706 Validation of the Δ SUV_{max} for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial**
Emmanuel Itti, Paul Blanc-Durand, Alina Berriolo-Riedinger, Salim Kanoun, Françoise Kraeber-Bodéré, Michel Meignan, Elodie Gat, Steven Le Gouill, René-Olivier Casanovas, and Caroline Bodet-Milin

- 1712 Impact of ⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers**

Stefan A. Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L. Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, et al.

THERANOSTICS

Clinical

- 1721 ■ BRIEF COMMUNICATION. Prediction of Resistance to ¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers**
Oliver Sartor, Elisa Ledet, Minqui Huang, Jennifer Schwartz, Alex Lieberman, Brian Lewis, Jodi Layton, Pedro Barata, Albert Jang, Madeline Hawkins, et al.
- 1726 ■ BRIEF COMMUNICATION. [¹⁷⁷Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial**
Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, and Shrawan Kumar Singh
- 1730 Antihormonal-Treatment Status Affects ⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer**
Kilian Kluge, David Haberl, Holger Einspieler, Sazan Rasul, Sebastian Gutschmayer, Lukas Kenner, Gero Kramer, Bernhard Grubmüller, Shahrokh Shariat, Alexander Haug, et al.
- 1737 Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with ¹⁷⁷Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis**
Vishnu Murthy, Andrei Gafita, Pan Thin, Kathleen Nguyen, Tristan Grogan, John Shen, Alexandra Drakaki, Matthew Rettig, Johannes Czernin, and Jeremie Calais
- 1744 ■ FEATURED ARTICLE OF THE MONTH. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers**
Thomas A. Hope, Matthias Benz, Fei Jiang, Daniel Thompson, Francesco Barbato, Roxana Juarez, Miguel Hernandez Pampaloni, Martin Allen-Auerbach, Pawan Gupta, Wolfgang P. Fendler, et al.
- 1748 ■ INVITED PERSPECTIVE. Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?**
Michal Eifer, Ramin Alipour, Michael S. Hofman, and Aravind S. Ravi Kumar
- 1750 A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study**
Jingliang Zhang, Fei Kang, Jie Gao, Jianhua Jiao, Zhiyong Quan, Shuaijun Ma, Yu Li, Shikuan Guo, Zeyu Li, Yuming Jing, et al.
- 1758 Prediction of Response to ¹⁷⁷Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC**
Melanie Hohberg, Manuel Reifegerst, Alexander Drzezga, Markus Wild, and Matthias Schmidt

1765 Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of ¹⁷⁷Lu-PSMA I&T

Amir Karimzadeh, Paula Soeiro, Benedikt Feurecker, Charlotte-Sophie Hecker, Karina Knorr, Matthias M. Heck, Robert Tauber, Calogero D'Alessandria, Wolfgang A. Weber, Matthias Eiber, et al.

Basic

1772 Tandem Isotope Therapy with ²²⁵Ac- and ¹⁷⁷Lu-PSMA-617 in a Murine Model of Prostate Cancer

Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Jeremie Calais, Johannes Czernin, Roger Slavik, and Magnus Dahlbom

RADIOBIOLOGY/DOSIMETRY

Clinical

1779 Lesion Dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer

Milan Grkovski, Joseph A. O'Donoghue, Brandon S. Imber, George Andl, Cheng Tu, Daniel Lafontaine, Jazmin Schwartz, Maria Thor, Michael J. Zelefsky, John L. Humm, et al.

1788 ■ BRIEF COMMUNICATION. Second Symposium of the European Working Group on the Radiobiology of Molecular Radionuclide Therapy

Julie Nonnekens, Bart Cornelissen, and Samantha Y.A. Terry

RADIOCHEMISTRY

Basic

1791 Optimized Methods for the Production of High-Purity ²⁰³Pb Using Electroplated Thallium Targets

Shefali Saini, Jennifer L. Bartels, Jean-Pierre K. Appiah, Jason H. Rider, Nicholas Baumhover, Michael K. Schultz, and Suzanne E. Lapi

NEUROLOGY

Clinical

1798 Biostatistical Estimation of Tau Threshold Hallmarks (BETH) Algorithm for Human Tau PET Imaging Studies

Alexandra Gogola, Brian J. Lopresti, Dana Tudorascu, Beth Snitz, Davneet Minhas, Vincent Doré, Milos D. Ikonovic, C. Elizabeth Shaaban, Cristy Matan, Pierrick Bourgeat, et al.

GASTROENTEROLOGY

Basic

1806 ■ FEATURED BASIC SCIENCE ARTICLE. Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease

Farzaneh Rezazadeh, Nicholas Ramos, Allen-Dexter Saliganan, Najeeb Al-Hallak, Kang Chen, Bashar Mohamad, Wendy N. Wiesend, and Nerissa T. Viola

PHYSICS AND INSTRUMENTATION

Clinical

1815 Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for ⁸⁹Zr-Trastuzumab

Philipp Mohr, Joyce van Sluis, Laura Providência, Johannes H. van Snick, Marjolijn N. Lub-de Hooge, Antoon T. Willemsen, Andor W.J.M. Glaudemans, Ronald Boellaard, Adriaan A. Lammertsma, Adrienne H. Brouwers, et al.

1821 Total-Body Multiparametric PET Quantification of ¹⁸F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery

Yiran Wang, Lorenzo Nardo, Benjamin A. Spencer, Yasser G. Abdelhafez, Elizabeth J. Li, Negar Omidvari, Abhijit J. Chaudhari, Ramsey D. Badawi, Terry Jones, Simon R. Cherry, et al.

1831 Total-Body Perfusion Imaging with [¹¹C]-Butanol

Elizabeth J. Li, Javier E. López, Benjamin A. Spencer, Yasser Abdelhafez, Ramsey D. Badawi, Guobao Wang, and Simon R. Cherry

ILLUSTRATED POST

1839 Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [⁶⁸Ga]Ga-FAPI-46 PET-Positive and [¹⁸F]FDG PET-Negative

Peter George Maliha, Abie H. Mendelsohn, Johannes Czernin, Taylor Howard, Jeremie Calais, and Masatoshi Hotta

LETTERS TO THE EDITOR

1841 HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Renske Altena, Siri af Burén, Thuy Tran, and Rimma Axelsson

1841 ■ REPLY. HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Romain-David Seban

DEPARTMENTS

10A This Month in JNM